136 related articles for article (PubMed ID: 27887672)
1. Cost of Cutaneous Melanoma by Tumor Stage: A Descriptive Analysis.
Serra-Arbeloa P; Rabines-Juárez ÁO; Álvarez-Ruiz MS; Guillén-Grima F
Actas Dermosifiliogr; 2017 Apr; 108(3):229-236. PubMed ID: 27887672
[TBL] [Abstract][Full Text] [Related]
2. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
Alexandrescu DT
Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
[TBL] [Abstract][Full Text] [Related]
3. Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines.
Buja A; Sartor G; Scioni M; Vecchiato A; Bolzan M; Rebba V; Sileni VC; Palozzo AC; Montesco M; Del Fiore P; Baldo V; Rossi CR
Acta Derm Venereol; 2018 Feb; 98(2):218-224. PubMed ID: 29110018
[TBL] [Abstract][Full Text] [Related]
4. An estimate of the annual direct cost of treating cutaneous melanoma.
Tsao H; Rogers GS; Sober AJ
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):669-80. PubMed ID: 9591809
[TBL] [Abstract][Full Text] [Related]
5. Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis.
Elliott TM; Whiteman DC; Olsen CM; Gordon LG
Appl Health Econ Health Policy; 2017 Dec; 15(6):805-816. PubMed ID: 28756584
[TBL] [Abstract][Full Text] [Related]
6. Stage-specific direct health care costs in patients with cutaneous malignant melanoma.
Lyth J; Carstensen J; Synnerstad I; Lindholm C
J Eur Acad Dermatol Venereol; 2016 May; 30(5):789-93. PubMed ID: 25807966
[TBL] [Abstract][Full Text] [Related]
7. An estimate of the cost of treating melanoma disease in the state of Sao Paulo - Brazil.
Souza RJ; Mattedi AP; Rezende ML; Corrêa Mde P; Duarte EM
An Bras Dermatol; 2009 Jul; 84(3):237-43. PubMed ID: 19668936
[TBL] [Abstract][Full Text] [Related]
8. Costs of the detection of metastases and follow-up examinations in cutaneous melanoma.
Leiter U; Marghoob AA; Lasithiotakis K; Eigentler TK; Meier F; Meisner C; Garbe C
Melanoma Res; 2009 Feb; 19(1):50-7. PubMed ID: 19430406
[TBL] [Abstract][Full Text] [Related]
9. Confirming the timing of phase-based costing in oncology studies: a case example in advanced melanoma.
Atkins M; Coutinho AD; Nunna S; Gupte-Singh K; Eaddy M
J Med Econ; 2018 Feb; 21(2):212-217. PubMed ID: 29022427
[TBL] [Abstract][Full Text] [Related]
10. [Descriptive study of the costs of diagnosis and treatment of cutaneous melanoma].
Almazán-Fernández FM; Serrano-Ortega S; Moreno-Villalonga JJ
Actas Dermosifiliogr; 2009 Nov; 100(9):785-91. PubMed ID: 19889300
[TBL] [Abstract][Full Text] [Related]
11. Health Outcomes and Direct Healthcare Costs in Patients with Melanoma: Associations with Level of Education.
Buja A; Rivera M; Zorzi M; Sperotto M; Baracco S; Italiano I; Vecchiato A; Del Fiore P; Avossa F; Corti MC; Guzzinati S; Saia M; Baldo V; Rugge M; Rossi CR
Acta Derm Venereol; 2020 Jan; 100(1):adv00003. PubMed ID: 31580466
[No Abstract] [Full Text] [Related]
12. Melanoma treatment costs: a systematic review of the literature, 1990-2011.
Guy GP; Ekwueme DU; Tangka FK; Richardson LC
Am J Prev Med; 2012 Nov; 43(5):537-45. PubMed ID: 23079178
[TBL] [Abstract][Full Text] [Related]
13. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.
Watts CG; Cust AE; Menzies SW; Mann GJ; Morton RL
J Clin Oncol; 2017 Jan; 35(1):63-71. PubMed ID: 28034073
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy.
Tromme I; Legrand C; Devleesschauwer B; Leiter U; Suciu S; Eggermont A; Sacré L; Baurain JF; Thomas L; Beutels P; Speybroeck N
Eur J Cancer; 2016 Nov; 67():38-45. PubMed ID: 27592070
[TBL] [Abstract][Full Text] [Related]
16. Differences in direct costs of patients with stage I cutaneous melanoma: A real-world data analysis.
Buja A; Rivera M; De Polo A; Zorzi M; Baracco M; Italiano I; Vecchiato A; Del Fiore P; Guzzinati S; Saia M; Baldo V; Rugge M; Rossi CR
Eur J Surg Oncol; 2020 Jun; 46(6):976-981. PubMed ID: 32146052
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of therapies for melanoma.
Johnston KM; McPherson E; Osenenko K; Vergidis J; Levy AR; Peacock S
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):229-42. PubMed ID: 25703441
[TBL] [Abstract][Full Text] [Related]
18. Sentinel node biopsy in patients with primary cutaneous melanoma of any thickness: A cost-effectiveness analysis.
Serra-Arbeloa P; Rabines-Juárez ÁO; Álvarez-Ruiz MS; Guillén-Grima F
Surg Oncol; 2016 Sep; 25(3):205-11. PubMed ID: 27566024
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
Bastiaannet E; Uyl-de Groot CA; Brouwers AH; van der Jagt EJ; Hoekstra OS; Oyen W; Verzijlbergen F; van Ooijen B; Thompson JF; Hoekstra HJ
Ann Surg; 2012 Apr; 255(4):771-6. PubMed ID: 22367443
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data.
Seidler AM; Pennie ML; Veledar E; Culler SD; Chen SC
Arch Dermatol; 2010 Mar; 146(3):249-56. PubMed ID: 20231494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
